What stem cells are used for: evidence and limits

Stem cells. What we know and what we do not yet.

When someone researches what stem cells are used for, they typically encounter two opposing narratives: one that promises a cure for nearly everything, and one that dismisses any application outside the laboratory. Neither is useful. What exists is a field with confirmed applications, active areas of investigation, and zones where the evidence does not yet support a clinical indication.

At Longevia Medical we work with regenerative judgment: distinguishing where each application stands is part of the assessment, not a minor detail. This article describes that map, with its boundaries.

What stem cells are and why understanding them matters

Stem cells are cells defined by two distinguishing properties: the capacity to renew themselves and the capacity to differentiate into more specialized cell types. Under the right conditions, a stem cell can become muscle, bone, nerve, or other tissue.

There are distinct categories based on origin and degree of plasticity. Embryonic stem cells have greater differentiation capacity but carry significant ethical and regulatory constraints. Adult stem cells, present in bone marrow, adipose tissue, and other tissues, have a more limited differentiation range but are the ones most used in current clinical applications. Induced stem cells, obtained by reprogramming adult cells, are under active investigation but do not yet have a generalized clinical use.

Understanding this distinction matters because not every stem cell does the same thing, and not every clinical context justifies their use. The indication depends on the cell type, the condition being addressed, and the overall health of the person receiving it.

The indication is not defined by enthusiasm for the treatment. It is defined by the assessment of the person who will receive it.

What stem cells are used for: applications with clinical support

The applications with the strongest clinical support are those with the longest track record in practice, with defined protocols and documented follow-up. The most established is hematopoietic stem cell transplantation, used in blood and immune system diseases such as certain types of leukemia, lymphoma, and aplastic anemia. In these cases, the objective is to rebuild a hematopoietic system damaged by the disease or by oncological treatment.

This use takes place in specialized hospital settings with continuous monitoring. It is not an outpatient procedure and is not performed in regenerative medicine clinics. Mentioning it here serves to clearly locate which part of the field is consolidated and under what conditions.

In the realm of outpatient regenerative medicine, the use of mesenchymal stem cells has indications under ongoing validation for joint, inflammatory, and tissue recovery conditions. The level of support varies by specific condition, and candidate selection is determining for the intervention to have clinical merit.

What remains under investigation: promising signals, not yet a protocol

There are areas where studies show signals of interest but where a validated clinical protocol for general use does not yet exist. Naming them honestly is part of the judgment we expect from any medical team.

Among the active lines of investigation are applications in neurological conditions such as amyotrophic lateral sclerosis and Parkinson's disease, spinal cord injuries, type 1 diabetes, and certain autoimmune diseases. In all these areas, clinical trials are ongoing, but results are not sufficient to establish a standard indication. Anyone who offers you a consolidated protocol for any of these conditions without distinguishing between available evidence and active research is not being precise.

In the context of longevity and preventive medicine, the use of stem cells is being investigated as a tool to modulate chronic inflammation, support the regeneration of aging tissues, and strengthen immune response. The biology of cellular aging is one of the most scientifically active fields today. At present, however, the protocols available in this area must be presented as part of a regenerative medicine plan with individual indication, rigorous follow-up, and reference biomarkers, not as routine treatments.

A therapy under investigation is not a therapy without value. It is a therapy whose indication is still being defined. That distinction matters.

flowchart TD
    A["Inquiry about stem cells"] --> B["Does a validated clinical protocol exist?"]
    B -->|"Yes"| C["Supported use: hematopoietic transplantation, defined mesenchymal indications"]
    B -->|"In progress"| D["Active investigation: neurology, autoimmunity, longevity"]
    B -->|"No"| E["No current clinical indication"]
    C --> F["Individual assessment for candidacy"]
    D --> F
    E --> G["Patient is clearly informed"]

What stem cells are not yet used for: limits the field acknowledges

Stating what stem cells are not used for, with current knowledge, is as important as describing their possible uses. There are conditions for which no established indication exists, and in those cases applying a regenerative therapy without a protocol is not cutting-edge medicine, it is clinical imprecision.

Stem cells do not regenerate irreversibly damaged central nervous tissue. They do not reverse advanced neurodegenerative diseases. They do not replace active oncological treatment. They do not correct structural genetic alterations. They do not produce predictable aesthetic results as a sole intervention. They are not a preventive treatment without indication: applying stem cells "just in case" or as a wellness supplement, without an assessment that justifies candidacy, has no clinical support.

This does not deny the field's potential. It places it in its current position: an area of medicine with real applications, active investigation, and limits that responsible teams acknowledge without hesitation.

How it is determined whether stem cell therapy applies in your case

Candidacy for any regenerative protocol is defined in an individual clinical assessment. No generic profile determines it: age, overall health status, available biomarkers, the therapeutic objective, and follow-up conditions are all factors the medical team weighs before proposing a plan.

For those researching what stem cells are used for with the intention of understanding whether they apply to their situation, the path begins there: in an assessment, not in a list of indications. If something applies, the plan is delivered in writing, with a defined protocol and follow-up. If it does not apply, that is also stated clearly.

At Longevia Medical, the assessment can be in person at Puerto Cancún or remote. Follow-up continues when the patient returns home. The head of the regenerative area is Dr. María Guadalupe Navarro Barrientos, Surgeon and Homeopathic Physician (IPN), with a Master's degree in Molecular Biomedicine (IPN) and a Doctorate in Medical Research from the Escuela Superior de Medicina del IPN.

If during or after any medical procedure you experience sudden changes in vision, difficulty breathing, chest pain, new neurological symptoms, or significant changes in skin color, go to the emergency room immediately. Those signals require emergency attention, not communication with a clinic.

Follow-up does not end when the patient returns home. It is part of the protocol, not an optional addition.

Stem cells in the context of longevity medicine

In the longevity field, mesenchymal stem cells are being investigated as one element of a broader protocol that may include aging biomarker analysis, body composition evaluation, and adjustments across other metabolic dimensions. The idea is not to apply stem cells in isolation but to integrate them, when there is an indication, into a plan that is reviewed over time.

Longevity medicine starts from a different premise than emergency medicine: the objective is not to resolve a crisis but to sustain functional capacity and reduce the biological burden of aging. Stem cells may have a place in that plan when the assessment justifies it. They may not, and in that case the clinical team directs toward the protocols that do apply.

To explore how candidacy for a regenerative therapy is evaluated with clinical judgment, you can read our article on stem cell therapy in Mexico: how to evaluate a clinic.

Frequently asked questions about stem cells

What are stem cells used for in older adults?

In older adults, stem cells are investigated primarily to modulate chronic inflammation and support tissue regeneration. Candidacy depends on an individual assessment with biomarkers: there is no standard protocol applicable to any person solely on the basis of age.

Do stem cells cure diseases?

The most established use is transplantation in hematological diseases such as certain types of leukemia and aplastic anemia. For other conditions, stem cells are under active investigation, not as an established cure. No responsible protocol promises a cure.

How many stem cell sessions are needed?

The number of sessions is part of the individual protocol and is defined during the assessment. It depends on the therapeutic objective, overall health status, and response to treatment. There is no standard number applicable to all cases.

Do stem cells work for aging?

This is one of the most active lines of investigation in longevity medicine. There are signals of interest regarding the modulation of cellular aging, but the available protocols require individual indication. It is not a routine or preventive treatment without prior assessment.

How do I know if I am a candidate for stem cell therapy?

Candidacy is determined in a clinical assessment, in person or remote. Biomarkers, overall health status, and the therapeutic objective are reviewed. If it applies, the plan is delivered in writing with a defined protocol and follow-up. If it does not apply, that is also communicated clearly.

For those who wish to continue reading from patient-oriented reference sources, Mayo Clinic and MedlinePlus offer general information on regenerative therapies and stem cells in accessible language.